Lumicell Names Marnie Curbow as Chief Commercial Officer in Bold Growth Move

Lumicell Elevates Marnie Curbow to Chief Commercial Officer

Lumicell, Inc., a trailblazer in cutting-edge fluorescence-guided imaging technologies for cancer detection, has made a significant leadership change. On May 28, 2026, the company announced the promotion of Marnie Curbow to Chief Commercial Officer (CCO). This strategic move is aimed at driving the next phase of growth for Lumicell, with Curbow at the helm of all commercial operations including sales, marketing, reimbursement, and clinical applications.

Marnie Curbow joined Lumicell just a few months prior in October 2025 as Vice President of Sales. In her brief tenure, she has rapidly expanded her influence across the organization, playing a pivotal role in building a new commercial team and enhancing the company's go-to-market strategy for its groundbreaking fluorescence-guided surgery platform.

Before her tenure at Lumicell, Curbow amassed an impressive 18-year career in the realm of breast oncology. Her expertise spans various domains including surgery, diagnostics, and therapeutic solutions. Most notably, she served as General Manager and VP of Sales Diagnostics for the Americas at Rhinomed, where she successfully introduced a novel diagnostic product and earned a SPARK accelerator award from BARDA. This extensive background has endowed her with a unique perspective that aligns well with Lumicell's mission to advance cancer detection and treatment.

In a statement, Dr. Andrey Zarur, Executive Chairman of Lumicell, praised Curbow's contributions, stating, "Marnie has been an exceptional addition to our leadership team. She has taken on more than what was initially expected and delivered consistently. This promotion reflects the magnitude of her impact and our trust in her leadership as we pursue commercial scale."

Curbow herself expressed her enthusiasm for her new role, emphasizing the strength of Lumicell's existing team and their commitment to the company's mission. She stated, "At Lumicell, we focus on bringing the light—both literally in the operating room and in how we engage with each other and our customers. What has struck me from day one is the caliber of the team here, individuals who are deeply committed to our mission and to one another. I'm thrilled to step into this role and enhance that foundation as we strive for outcomes that genuinely matter for patients and surgeons. I look forward to achieving great things together."

The technology Lumicell offers is a fluorescence-guided surgery system, which assists surgeons in identifying and excising residual cancer tissue during lumpectomy procedures, ultimately improving surgical results. The FDA granted approval for this innovative technology in April 2024, and it is currently being utilized in hospitals throughout the United States.

About Lumicell

Lumicell stands at the forefront of revolutionizing intraoperative cancer detection through real-time fluorescence imaging technology. The company’s proprietary systems have received FDA approval for breast cancer treatment and are also undergoing development for various other solid tumor indications. To learn more about Lumicell, visit www.Lumicell.com and explore further at www.Lumisystem.com. Additionally, follow them on social media platforms like Facebook, X, and LinkedIn to stay updated on their latest advancements.